Know Cancer

forgot password

A Phase II Study of Irinotecan and Panitumumab as 3rd Line Treatment of Patients With Metastatic Colorectal Cancer Without KRAS Mutations

Phase 2
18 Years
Not Enrolling
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase II Study of Irinotecan and Panitumumab as 3rd Line Treatment of Patients With Metastatic Colorectal Cancer Without KRAS Mutations

Colorectal cancer is one of the most frequent types of cancer in Denmark with approximately
3,400 diagnosed patients per year. The prognosis for these patients is still very poor and
more than half of them will develop metastatic disease and thus be candidates for

In Denmark 5-FU and Oxaliplatin or Irinotecan has been used for several years either as
combination or mono therapy. In recent years biological antibodies targeted against EGFR
have been added to this treatment. A newly developed antibody is Panitumumab, which enables
treatment every 3 weeks instead of weekly administration.

The effect of EGFR activation is mediated through intracellular pathways involving the KRAS
protein. It has been proven that a mutation of KRAS causes the KRAS protein to be constantly
activated, and patients with these mutations do not benefit from antibodies against EGFR.
Approximately 40% of the patients present these mutations.

Inclusion Criteria:

- Histologically verified adenocarcinoma in colon or rectum with metastatic spread.

- No mutations in the KRAS gene.

- Resistance to 5-FU, oxaliplatin and irinotecan.

- Age ≥18 years.

- PS 0-2.

- Measurable disease according to RECIST criteria.

- Haematology: Neutrophilocytes ≥1.5 x 109/l, leukocytes ≥3.0 x 109/l, thrombocytes
≥100 and bilirubinaemia ≤3 x upper normal value. Samples no more than 4 weeks old.

- Fertile women must present a negative pregnancy test and use secure birth control
during and 3 months after treatment.

- Acceptance that blod and tissue samples are kept for subsequent investigation of

- Oral and written informed consent.

Exclusion Criteria:

- Other malignant disease within the past 5 years, excl. non-melanoma skin cancer and
carcinoma in situ cervicis uteri.

- Chemotherapy, radiotherapy or immunotherapy within the past 4 weeks.

- Verified or clinically suspected CNS metastasis.

- Other experimental treatment.

- Serious medical disease according to investigator's judgement.

- Pregnant or breastfeeding women.

- Hypersensitivity to the active substance or to one or more of the auxiliary

- Patients with interstitial pneumonitis or pulmonary fibrosis.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response Rate

Outcome Time Frame:

Every 9 weeks. Up to 6 months

Safety Issue:


Principal Investigator

Anders Jakobsen, Professor

Investigator Role:

Study Chair

Investigator Affiliation:

Vejle Hospital


Denmark: National Board of Health

Study ID:

EudraCT 2008-004923-48



Start Date:

November 2008

Completion Date:

August 2011

Related Keywords:

  • Metastatic Colorectal Cancer
  • KRAS
  • Colorectal Neoplasms